Join
Live feed
·
INSIDERFilingvia Quantisnow
Entrada Therapeutics Inc. logo

President, Research & Develop. Sethuraman Natarajan sold $398,810 worth of shares (25,907 units at $15.39) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 216,317 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
TRDA· Entrada Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TRDA (Entrada Therapeutics Inc.) and more on Quantisnow.